The effect of killer cell immunoglobulin-like receptor genotype on outcome of hematopoietic stem cell transplantation from matched sibling

Hum Immunol. 2017 Nov;78(11-12):684-691. doi: 10.1016/j.humimm.2017.10.004. Epub 2017 Oct 7.

Abstract

The alloreactivity of natural killer (NK) cell after allogeneic hematopoietic stem cell transplantation (AHSCT) is regulated by the interaction between donor killer immunoglobulin-like receptors (KIRs) and recipient human leukocyte antigen (HLA)-class I molecules. The aim was to identify KIR genes, haplotypes and their HLA-class I ligands and to investigate their association with transplantation outcome. The study included 65 patient/donor pairs who received AHSCT from HLA-matched identical siblings. KIR genotyping was done for donors using reverse sequence specific oligonucleotide probes (rSSO) coupled with luminex technology, while HLA-C genotyping was performed in patients using rSSO strip assay. In multivariate analysis, KIR2DS4 was associated with significant reduced incidence of relapse (p = .002). A trend towards reduced incidence of relapse was also observed with more than two KIR B motifs (p = .09), whereas a significant increased relapse was associated with homozygous HLA-C2 ligand compared to combined C1/C2 and C1/C1 (p = .04). Activating KIR2DS3 was associated with rapid leukocyte engraftment (p = .02). While, KIR 2DL5 was associated with decreased CMV infection (p = .03) and better platelets engraftment (p = .05). KIR genes, haplotypes and HLA-C alleles have an impact on HSCT outcome. Better selection of donors with favorable KIR genotype can improve HLA-matched sibling HSCT outcome especially for AML patients.

Keywords: Allogeneic hematopoietic stem cell transplantation; Killer immunoglobulin-like receptor; NK cell; Relapse.

MeSH terms

  • Adolescent
  • Adult
  • Child
  • Female
  • Genotype
  • HLA-C Antigens / genetics
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility
  • Histocompatibility Testing
  • Humans
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Polymorphism, Genetic
  • Receptors, KIR / genetics*
  • Receptors, KIR2DL5 / genetics*
  • Siblings
  • Transplantation Tolerance
  • Young Adult

Substances

  • HLA-C Antigens
  • KIR2DS3 protein, human
  • KIR2DS4 protein, human
  • Receptors, KIR
  • Receptors, KIR2DL5